Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1
Monica Autiero,Johannes Waltenberger,Didier Communi,Andrea Kranz,Lieve Moons,Diether Lambrechts,Jens Kroll,Stephane Plaisance,Maria De Mol,Françoise Bono,Stefanie Kliche,Guido Fellbrich,Kurt Ballmer-Hofer,Domenico Maglione,Ulrike Mayr-Beyrle,Mieke Dewerchin,Saskia Dombrowski,Danica Stanimirovic,Paul Van Hummelen,Christoph Dehio,Daniel J Hicklin,Graziella Persico,Jean-Marc Herbert,David Communi,Masabumi Shibuya,Désiré Collen,Edward M Conway,Peter Carmeliet
DOI: https://doi.org/10.1038/nm884
IF: 82.9
2003-06-08
Nature Medicine
Abstract:Therapeutic angiogenesis is likely to require the administration of factors that complement each other. Activation of the receptor tyrosine kinase (RTK) Flk1 by vascular endothelial growth factor (VEGF) is crucial, but molecular interactions of other factors with VEGF and Flk1 have been studied to a limited extent. Here we report that placental growth factor (PGF, also known as PlGF) regulates inter- and intramolecular cross talk between the VEGF RTKs Flt1 and Flk1. Activation of Flt1 by PGF resulted in intermolecular transphosphorylation of Flk1, thereby amplifying VEGF-driven angiogenesis through Flk1. Even though VEGF and PGF both bind Flt1, PGF uniquely stimulated the phosphorylation of specific Flt1 tyrosine residues and the expression of distinct downstream target genes. Furthermore, the VEGF/PGF heterodimer activated intramolecular VEGF receptor cross talk through formation of Flk1/Flt1 heterodimers. The inter- and intramolecular VEGF receptor cross talk is likely to have therapeutic implications, as treatment with VEGF/PGF heterodimer or a combination of VEGF plus PGF increased ischemic myocardial angiogenesis in a mouse model that was refractory to VEGF alone.
biochemistry & molecular biology,cell biology,medicine, research & experimental